To Evaluate if the Medication Gabapentin Lessens Vulvar Pain
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this research study is to evaluate if the medication gabapentin lessens the vulvar pain some women experience.
| Condition | Intervention |
|---|---|
|
Vulvar Pain Symptoms Vulvodynia (Chronic Vulvar Pain) Vulvar Vestibulitis Syndrome (Chronic Vulvar Pain Localized to the Vaginal Opening) |
Drug: Gabapentin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Treatment |
| Official Title: | Vulvar Pain: Treatment Trial Using Gabapentin-Placebo in a Cross-Over Design, Pilot Study. |
- The efficacy of gabapentin to decrease vulvar pain compared to placebo will be determined at the 8 and 19 week follow up visits, by reported change in vulvar pain. [ Time Frame: 19 weeks ] [ Designated as safety issue: No ]
- Change in dyspareunia and burning symptom scores and change in clinical appearance and qualitative and quantitive tests performed will be compared at the 8 and 19 week follow up visits. [ Time Frame: 19 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | January 2007 |
| Study Completion Date: | March 2008 |
| Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
-
Drug: Gabapentin
- day 1 you will take 1 capsule for the day
- day 2 you will take 1 capsule 2 times for that day
- days 3-6 you will take 1 capsule 3 times for those days
- days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day
- days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day
- days 13-14 you will take 2 capsules 3 times each day
- continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.
- at completion of study treatment you will titrate off study drug over a weeks time.
300 mg. capsules
Dosage schedule for weeks 1 and 2 and weeks 12 and 13:
There is not a "best" treatment plan for vulvar pain including vulvodynia (chronic vulvar pain) and vulvar vestibulitis syndrome (VVS, chronic vulvar pain localized to the vaginal opening). We propose that vulvodynia is a neuropathic pain (pain that effects the nervous system) as characterized by pain from stimuli that is not usually painful, stimuli that would not usually be painful causing significant pain, and burning pain. Gabapentin has been shown to be effective in treating chronic pain.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- All women, ages 18 years and older with the diagnosis of vulvodynia or VVS (by Friedrich's criteria), who present to the University of Iowa Vulvar Vaginal Disease Clinic.
Exclusion Criteria:
- Vulvar Vaginal Disease clinic patients who are pregnant, less than 3 months postpartum, breast-feeding, non-English speaking, or have contraindication to use of gabapentin due to allergy or renal disease (serum creatinine level greater than 1.4).
Contacts and Locations| United States, Iowa | |
| University of Iowa Hospital and Clinics | |
| Iowa City, Iowa, United States, 52242 | |
| Principal Investigator: | Colleen M. Kennedy, M.D., M.S. | University of Iowa Hospital and Clinics, Department of Ob/Gyn |
More Information
No publications provided
| Responsible Party: | Colleen M. Kennedy, M.D., M.S., University of Iowa |
| ClinicalTrials.gov Identifier: | NCT00390013 History of Changes |
| Other Study ID Numbers: | 243-3225-53540306 Kennedy GCRC, RR00059, 200606748 |
| Study First Received: | October 18, 2006 |
| Last Updated: | March 12, 2009 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Iowa:
|
Vulvar Pain |
Additional relevant MeSH terms:
|
Vulvodynia Vulvar Vestibulitis Vulvitis Vulvar Diseases Genital Diseases, Female Gabapentin Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anticonvulsants |
Antiparkinson Agents Anti-Dyskinesia Agents Calcium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Cardiovascular Agents Anti-Anxiety Agents Tranquilizing Agents Central Nervous System Depressants Psychotropic Drugs Excitatory Amino Acid Antagonists Excitatory Amino Acid Agents Neurotransmitter Agents Antimanic Agents |
ClinicalTrials.gov processed this record on May 16, 2013